)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Exelixis
Exelixis (EXEL) investor relations material
Exelixis Morgan Stanley 24th Annual Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Morgan Stanley 24th Annual Global Healthcare Conference summary15 Sep, 2026
Innovation and portfolio strategy
China-originated biotech activity is expanding; diligence prioritizes novel assets over fast followers and me-too programs, with collaboration viewed as a preferred route to broaden franchises.
Portfolio strategy centers on multiple products and franchises, building on cabozantinib with zanzalintinib and considering acquisitions, partnerships, collaborations, and ex-U.S. assets.
AI and policy environment
AI deployment is controlled and prioritized around decades of curated discovery, development, and commercial data; investment emphasizes speed, quality, and security, with potential to strengthen commercial capabilities.
Pricing and MFN are key policy concerns; planning considers near-term conditions through the 2026 midterms, the 2028 election and administration, and the early 2030s.
Cabozantinib franchise
Q2 2026 global run rate exceeded $3B annually; cabozantinib has eight labeled indications and remains the platform for expanding the franchise and developing zanzalintinib.
NET growth is running below expectations, extending the time to reach its potential; management said this does not change its view of the opportunity.
Several generic settlements set an entry date of Jan. 1, 2031; litigation continues with other challengers, and management cited a supportive recent appellate decision.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Exelixis
- Q4 revenue rose 13% as CABOMETYX expansion and pipeline growth shaped 2024 priorities.EXEL
Q4 2023 - CABOMETYX and zanzalintinib drive growth across oncology franchises, with AI boosting efficiency.EXELCitigroup’s Biopharma Back to School Summit 2026
- CABO and zanza drive growth, with immediate CRC launch readiness and robust pipeline plans.EXELWells Fargo 21st Annual Healthcare Conference
- Q2 2026 revenue rose 11% to $629M, with strong cabozantinib sales and zanzalintinib NDA review.EXELQ2 2026
- Six pivotal Zanza studies and a $5B market aim drive growth through strategic partnerships and trial innovation.EXELJefferies Global Healthcare Conference 2025
- CABOMETYX and zanza drive oncology growth, with disciplined investment fueling pipeline and returns.EXELMorgan Stanley 23rd Annual Global Healthcare Conference
- Q2 2025 net product revenues rose 19% to $520M, driven by CABOMETYX and NET launch.EXELQ2 2025
- Q3 revenues up 14%, guidance raised, and patent win secures cabozantinib exclusivity to 2030.EXELQ3 2024
- Q1 2025 revenue and net income surged, guidance was raised, and CABOMETYX led growth.EXELQ1 2025
Next Exelixis earnings date
Q3 202629 Oct, 2026
Exelixis
Next Exelixis earnings date
Q3 202629 Oct, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Exelixis Inc is a biotechnology company focused on developing and commercializing small molecule therapies for cancer treatment. The company engages in drug discovery, clinical development, and partnerships targeting multiple oncology indications. The company is headquartered in Alameda, California, and its shares are listed on the NASDAQ.